Skip to content

Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes

Safety and Efficacy of Low Carbohydrate Diet in Obesity and Type 2 DM: RCT

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00108459
Enrollment
156
Registered
2005-04-18
Start date
2004-09-30
Completion date
2007-12-31
Last updated
2009-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia, Obesity, Type 2 Diabetes

Keywords

Obesity, Type 2 Diabetes, Hyperlipidemia, Insulin resistance

Brief summary

This study is designed to address the hypothesis that in obese patients with type 2 diabetes mellitus (DM), a low carbohydrate diet not specifically restricted in calories compared to low fat, caloric restricted diet over 24 months will cause 5% greater reduction in body weight in patients with obesity and type 2 DM, be safe, and will not have any detrimental effects on serum lipid concentrations.

Detailed description

Objectives: This study is designed to address the hypothesis that in obese patients with type 2 DM, a low carbohydrate diet not specifically restricted in calories compared to low fat, caloric restricted diet over a 24 months period will: * Primary: 1. Cause 5% greater reduction in body weight in patients with obesity and type 2 DM; 2. Be safe and will not have any detrimental effects on serum lipid concentrations * Secondary: 1. Lead to a greater reduction in HbA1c and fasting serum glucose and insulin concentration; 2. Lead to reduction in body fat content; 3. Cause greater reduction in serum triglyceride concentration; 4. Cause no significant changes in proteinuria, serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), creatinine and uric acid concentrations * Exploratory: Cause favorable changes in adipocytokines (serum leptin, resistin, TNF-α, TNF α- receptors, free fatty acids) and high sensitive C-reactive protein Research Design: This will be a single site (Philadelphia VA Medical Center); two arm, parallel, randomized, clinical trial. Obese, male, type 2 diabetic subjects (body mass index \[BMI\] \>30 kg/m2) will be randomized in a 1:1 fashion to dietary instructions for low carbohydrate or low fat diet. Women will be randomized separately (blocks of 4) to ensure equal representation in both dietary groups. Recruitment will be done in 3 phases (for logistical reasons). Subjects will be randomized to one of the two dietary groups. One group will be instructed on a carbohydrate-restricted diet, and the other on a calorie and fat restricted diet as recommended by the National Heart, Lung and Blood Institute (NHLBI). All patients will have blood, urine, and body composition analyses measured at baseline and then at 26, 52, and 104 weeks. Dietary instructions will be given to subjects in groups of 13, and will be provided every week for the first 4 weeks and then every 4 weeks for a total of 30 visits. Methodology: The setting is the outpatient clinics of the Philadelphia Veterans Affairs Medical Center. Inclusion criteria include: Male or female subjects \> 18 years of age; Clinical diagnosis of type 2 diabetes mellitus; Body mass index of \> 30 kg/m2 . Approximately 156 male and female veterans from the Philadelphia Veterans Affairs Medical Center will be enrolled in this study.

Interventions

BEHAVIORALLow Carbohydrate Diet

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female subjects \> 18 years of age * Clinical diagnosis of type 2 diabetes mellitus or on insulin or oral hypoglycemic agents * Body mass index of \> 30 kg/m2 * The subject must we willing and able to monitor their blood glucose with a glucometer at least 2 times per week.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026